Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:37:31.665Z.
Consensus retrieved: 2026-10-06T12:40:54.837Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:37:31.665Z.
Quote observation: 2026-10-06T16:31:24.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3f3fe5cfad96663d45aee285232b63282d401ce5a2dce1ebe999e7f7af3a8937
Forward PE Ratio (N/A) = Dated Quote Price ($4.75) / Consensus Forward EPS ($-3.22)
FORWARD PE RATIO
N/A
ImageneBio Inc
Market Cap
$53.63M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| ImageneBio Inc (IMA) | $53.63M | N/A |
| Spectral AI, Inc. (MDAI)vs › | $53.62M | N/A |
| Aldeyra The (ALDX)vs › | $53.22M | N/A |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $52.46M | N/A |
| NOMAD Power Solutions, Inc. (NMAD)vs › | $52.28M | N/A |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $52.09M | N/A |
| biote Corp. (BTMD)vs › | $51.61M | N/A |
| eXoZymes, Inc. (EXOZ)vs › | $51.42M | N/A |
| Rani Therapeutics Holdings, Inc. (RANI)vs › | $51.20M | N/A |
| Clene Inc. (CLNN)vs › | $51.05M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $4.75, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-3.22 | $-3.56 – $-2.94 | 3 | n/m |
| 2027-12-31 | $-3.48 | $-5.24 – $-0.94 | 3 | n/m |
| 2028-12-31 | $-3.75 | $-5.07 – $-0.72 | 4 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
